Sildenafil and analogous phosphodiesterase type 5 (PDE-5) inhibitors in herbal food supplements sampled on the Dutch market

Food Additives and Contaminants - Part A

Volumn 30, Issue 12, 2013, Pages 2027-2034

  Reeuwijk, N M ^a   Venhuis, B J ^b   de Kaste, D ^b   Hoogenboom, L A P ^c   Rietjens, I M C M ^c   Martena, M J ^d  

^a Netherlands Food and Consumer Product Safety Authority (NVWA)   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c WAGENINGEN UNIVERSITY   (Netherlands)

^d Ministry of Health Welfare and Sport Netherlands   (Netherlands)

Author keywords

erectile dysfunction; health risk; herbal food supplements; phosphodiesterase type 5 inhibitors; sildenafil; structural analogues; tadalafil; vardenafil

Indexed keywords

BEVERAGES; COMMERCE; DRUG DOSAGE; HEALTH RISKS;

ERECTILE DYSFUNCTION; FOOD SUPPLEMENTS; PHOSPHODIESTERASES; SILDENAFIL; STRUCTURAL ANALOGUE; TADALAFIL; VARDENAFIL;

ESTERS;

ACETILDENAFIL; AILDENAFIL; AMINOTADALAFIL; HOMOHYDROXYSILDENAFIL; NORACETILDENAFIL; PHOSPHODIESTERASE V; PIPERIDINO VARDENAFIL; SILDENAFIL; TADALAFIL; THIOAILDENAFIL; THIOSILDENAFIL; UNCLASSIFIED DRUG; VARDENAFIL;

ARTICLE; DIET SUPPLEMENTATION; DRUG STRUCTURE; ENZYME ACTIVITY; GERMANY; HERBAL MEDICINE; PRIORITY JOURNAL;

APIS;

CARBONATED BEVERAGES; CONSUMER PRODUCT SAFETY; DIETARY SUPPLEMENTS; ERECTILE DYSFUNCTION; FOOD CONTAMINATION; FOOD LABELING; GUIDELINE ADHERENCE; HUMANS; INTERNET; LEGISLATION, DRUG; LEGISLATION, FOOD; MALE; NETHERLANDS; PERFORMANCE-ENHANCING SUBSTANCES; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PLANTS, MEDICINAL; PUBLIC HEALTH SURVEILLANCE; PURINES; SEXUAL BEHAVIOR; SULFONES; VASODILATOR AGENTS;

EID: 84890789367     PISSN: 19440049     EISSN: 14645122     Source Type: Journal    
DOI: 10.1080/19440049.2013.848294     Document Type: Article

References (55)

1. Bell AS, Brown D, Terrett NK, inventors; Pfizer-Research-and-Development-Company, assignee. 1992 Feb 2. Pyralozopyrimidone antianginal agents. Patent 0463756 A1.
2. Blok-Tip L, Zomer B, Bakker F, Hartog KD, Hamzink M, ten Hove J, Vredenbregt M, de Kaste D. 2004. Structure elucidation of sildenafil analogues in herbal products. Food Add Contam. 21:737-748.
3. Boden WE, Aloke AV, Finn V, Patel D, Peacock WF, Thadani U, Zimmerman FH. 2012. Nitrates as an integral part of optimal medical therapy and cardiac rehabilitation for stable angina: review of current concepts and therapeutics. Clin Cardiol. 35:263-271.
4. Cho EY, Chung S-H, Kim JH, Kim D-H, Jin C. 2003. Effects of a new selective phosphodiesterase type 5 inhibitor, KJH-1002, on the relaxation of rabbit corpus cavernosum tissue. J Appl Pharmacol. 11:232-237.
5. Codevilla CF, Machado Lemos A, Shreiner Delgado L, Bueno Rolim CM, Horn Adams AI, Bergold AM. 2011. Development and validation of a stability-indicating LC method for the assay of lodenafil carbonate in tablets. J Chromatogr Sci. 49:502-507.
6. Corbin JD, Francis SH. 2002. Pharmacology of phosphodiesterease-5 inhibitors. Int J Clin Pract. 56:453-459.
7. Corbin JD, Francis SH, Webb DJ. 2002. Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction. Urology. 60:4-11.
8. Dale DJ, Dunn PJ, Golightly C, Hughes ML, Levett PC, Pearce AK, Searle PM, Ward G, Wood AS. 2000. The chemical development of the commercial route to sildenafil: a case history. Org Process Res Dev. 4:17-22.
9. Daugan AC, Gellibert F, Orme MW, Sawyer JS, Schultze LM; inventors. 2001 May 15. Pirazino. [1',2':1,6] Pyrido [3,4b] Indole derivatives. Patent WO2002/00656 A2.
10. EFSA. 2009. Guidance on safety assessment of botanicals and botanical preparations intended for use as ingredients in food supplements EFSA J. 7:1249.
11. Elder DP, Snodin D, Teasdale A. 2011. Control and analysis of hydrazine, hydrazides and hydrazone-genotoxic impurities in active pharmaceutical ingredients (APIs) and drug products. J Pharmaceut Biomed. 54:900-910.
12. Ellis P, Terrett NK, inventors; Pfizer, assignee. 1994. Pfizer-Research-and-Development-Company, Pyralozopyrimidones for the treatment of impotence. Patent WO94/28902.
13. EMA. 2013a. European public assessment report (APA) on Viagra [Internet]. Last updated on 09/2008. London: European Medicines Agency; [cited 2013 May 3]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human /00 0202/WC500049824.pdf
14. EMA. 2013b. EPAR summary for the public on Revatio [Internet]. Last updated on 02/2012. London: European Medicines Agency; [cited 2013 May 2]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000638/WC500055835.pdf
15. EMA. 2013c. EPAR summary for the public on Levitra [Internet]. Last updated on 03/2012. London: European Medicines Agency; [cited 2013 May 3]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000475/WC500039993.pdf
16. EMA. 2013d. EPAR summary for the public on Cialis [Internet]. Last updated on 11/2012. London: European Medicines Agency; [cited 2013 May 3]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000436/WC500026312.pdf
17. EMA. 2013e. EPAR summary for the public on Adcirca [Internet]. Last updated on 08/2012. London: European Medicines Agency; [cited 2013 May 2]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/001021/WC500032786.pdf
18. European Court of Justice [Internet]. 2009. Hecht-Pharma GmbH v Staatliches Gewerbeaufsichtsamt Lüneburg. Case C 140/07. European Court reports 2009. Page I-0004. Available from: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:62007CJ0140:EN:HTML
19. FDA. 2013. Tainted sexual enhancement products [Internet]. Silver Spring (MD): Food and Drug Administration; [cited 2013 May 2]. Available from: http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/MedicationHealthFraud/ucm234539.htm
20. Flores Toque HA, Priviero FBM, Teixeira CE, Perissutti E, Fiorino F, Severino B, Frecentese F, Lorenzetti R, Baracat JS, Santagada V, et al. 2008. Synthesis and pharmacological evaluations of sildenafil analogues for treatment of erectile dysfunction. J Med Chem. 51:2807-2815.
21. Göker H, Coşkun M, Ayhan-Ki{dotless}lci{dotless}gil G. 2012. Chromatographic separation and identification of sildenafil and yohimbine analogues illegally added in herbal supplements. In: Sasikumar D, editor. Chromatography and its applications. Croatia: InTech; [cited 2013 Sep 16]. Available from: http://www.intechopen.com/books/chromatography-and-its-applications/chromatographic-seperation-and-identification-of-a-sildenafil-and-yohimbine-analogue-illegally-added
22. Guo J, Li S, Ren J, Zhao Y, inventors; Institue of Radiation Medicine Academy of Military Medical Sciences, assignee; 2006 Aug 30; Pyrazolopyrimidinethione derivatives, salts and solvates thereof, preparation methods and use thereof. Patent US 2007/0219220 A1.
23. Gresser U, Gleiter CH. 2002. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil. Review of the literature. Eur J Med Res. 7:435-446.
24. Häberli A, Girard P, Low M-Y GeX. 2010. Isolation and structure elucidation of an interaction product of aminotadalafil found in an illegal health food product. J Pharmaceut Biomed Anal. 53:24-28.
25. Hasegawa T, Saijo M, Ishii T, Nagata T, Haishima Y, Kawahara N, Goda Y. 2008. Structural elucidation of a tadalafil analogue found in a dietary supplement. J Food Hyg Soc Japan. 49:311-315.
26. He ZJ, Zhang K, Jin J, Li NC, Na YQ, Bai WJ, Wang XF, Zhu JC, Jiang H, Yuan RP, et al. 2006. Aildenafil citrate: a new potent and highly selective phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction (abstract). Zhonghua Nan Ke Xue. 12:1080-1083. Chinese.
27. Kee C-L, Ge X, Koh H-L, Low M-Y. 2012. Isolation and characterization of propoxyphenyl linked sildenafil and thiosildenafil analogues in health supplements. J Pharmaceut Biomed Anal. 70:265-271.
28. Kloner R. 2007. Erectile dysfunction and hypertension; review. Int J Impot Res. 19:296-302.
29. Lee JH, Kim NS, Han KM, Kim SH, Cho S, Kim WS. 2013. Monitoring by LC-MS/MS of 48 compounds of sildenafil, tadalafil, vardenafil and their analogues in illicit health food products in the Korean market advertised as enhancing male sexual performance. Food Addit Contam. 30:1849-1857.
30. Li L, Low M-Y, Ge X, Bloodworth BC, Koh H-L. 2009. Isolation and structural elucidation of dapoxetine as an adulterant in a health supplement used for sexual performance enhancement. J Pharmaceut Biomed Anal. 50:724-728.
31. Lin M-C, Liu Y-C, Lin J-H. 2006. Identification of a sildenafil analogue adulterated in two herbal food supplements. J Food Drug Anal. 14:260-264.
32. Liu B, inventor; 2005 Nov 1. 1,6,dihydro-7H-pyrazolo[3,4-D]pyrimidin-7-one compound for the treatment of impotence. Patent US6960592 B2 10/736,732.
33. Mayrhofer A, Hackl A, Urban E. 2012. Vom SPICE-Problem zum NPSG -Legal Highs-. ÖAZ. 26:44-47.
34. McMahon CG. 2012. Dapoxetine: a new option in the medical management of premature ejaculation. Ther Adv Urol. 4:233-251.
35. NIH. 1993. Consensus development panel on impotence. NIH Consensus Conference. J Am Med Assoc. 270:83-90.
36. Niewöhner U, Es-Sayed M, Haning H, Schenke T, Schlemmer K-H, Keldenich J, Bischoff Erwin, Perzborn E, Dembowsky K, Serno P, Nowakowski M, inventors; 1999 May 20. 2-Phenylsubstituted imidazotriazinones as phosphodiesterase inhibitors. WO/1999/024433
37. Oh SS-Y, Zou P, Low M-Y, Koh H-L. 2006. Detection of sildenafil analogues in herbal products for erectile dysfunction. J Toxicol Environ Health. 69:1951-1958.
38. Pissarnitski D. 2006. Phosphodiesterase 5 (PDE 5) inhibitors for the treatment of male erectile disorder: attaining selectivity versus PDE-6. Med Res Rev. 26:369-395.
39. Reepmeyer JC, Woodruff JT. 2007. Use of liquid chromatography-mass spectrometry and a chemical cleavage reaction for the structure elucidation of a new sildenafil analogue detected as an adulterant in an herbal dietary supplement. J Pharmaceut Biomed. 4:887-893.
40. Reepmeyer JC, Woodruff JT, d'Avignon A. 2007. Structure elucidation of a novel analogue of sildenafil detected as an adulterant in a herbal dietary supplement. J Pharm Biomed Anal. 43:1615-1621.
41. RIVM. 2007. Recent developments in counterfeits and imitations of Viagra, Cialis and Levitra. A 2005-2007 update [Internet]. RIVM Report 370020001/2007. Bilthoven: RIVM; [cited 2013 Mar 4]. Available from: http://www.rivm.nl/bibliotheek/rapporten/370030001.pdf
42. RIVM. 2010. Illicit erectile dysfunction products in the Netherlands. A decade of trends and a 2007-2010 product update [Internet]. RIVM Report 370030003/2010. Bilthoven: RIVM; [cited 2013 Mar 4]. Available from: http://www.rivm.nl/bibliotheek/rapporten/370030003.pdf
43. Savaliya AA, Shah RP, Prasad B, Singh S. 2010. Screening of Indian aphrodisiac ayurvedic/herbal healthcare products for adulteration with sildanafil, tadalafil and/or vardenafil using LC/PDA and extracted ion LC-MS/TOF. J Pharm Biomed Anal. 52:406-409.
44. Shin C, Hong M, Kim D, Lim Y. 2004. Structure determination of a sildenafil analogue contained in commercial herb drinks. Magn Reson Chem. 42:1060-1062.
45. Singh S, Prasad B, Savaliya AA, Shah RP, Gohil VM, Kaur A. 2009. Strategies for characterizing sildenafil, vardenafil, tadalafil and their analogues in herbal dietary supplements, and detecting counterfeit products containing these drugs. Trends Anal Chem. 28:13-28.
46. Toque HA, Teixeira CE, Lorenzetti R, Okuyama CE, Antures E, De Nucci G. 2008. Pharmacological characterization of a novel phosphodiesterase type 5 (PDE5) inhibitor lodenafil carbonate on human and rabbit corpus cavernosum. Eur J Pharmacol. 591:189-195.
47. Venhuis BJ, Blok-Tip L, de Kaste D. 2008a. Designer drugs in herbal aphrodisiacs. Forensic Sci Int. 177:e25-e27.
48. Venhuis BJ, de Kaste D. 2012. Towards a decade of detecting new analogues of sildenafil, tadalafil and vardenafil in food supplements: a history, analytical aspects and health risks. J Pharm Biomed Anal. 69:196-208.
49. Venhuis BJ, Zomer G, de Kaste D. 2008b. Structure elucidation of a novel synthetic thiono analogue of sildenafil detected in an alleged herbal aphrodisiac. J Pharm Biomed Anal. 46:814-817.
50. Venhuis BJ, Zomer G, Hamzink M, Meiring HD, Aubin Y, de Kaste D. 2011. The identification of a nitrosated prodrug of the PDE-5 inhibitor aildenafil in a dietary supplement: a Viagra with a pop. J Pharm Biomed Anal. 54:735-741.
51. Venhuis BJ, Zomer G, Vredenbregt MJ, de Kaste D. 2010. The identification of (-)-trans-tadalafil, tadalafil, and sildenafil in counterfeit Cialis® and the optical purity of tadalafil stereoisomers. J Pharm Biomed Anal. 51:723-727.
52. Wang J, Jiang Y, Wang Y, Zhao X, Cui Y, Gu J. 2007. Liquid chromatography tandem mass spectrometry assay to determine the pharmacokinetics of aildenafil in human plasma. J Pharm Biomed Anal. 44:231-235.
53. Wollein U, Eisenreich W, Schramek N. 2011. Identification of novel sildenafil-analogues in an adulterated herbal food supplement. J Pharm Biomed Anal. 56:705-712.
54. Yee S-K, Chu S-S, Xu Y-M, Choo P-L. 2005. Regulatory control of Chinese proprietary medicines in Singapore. Health Pol. 71:133-149.
55. Zou P, Hou P, Low M-Y, Kou H-L. 2006. Structural elucidation of a tadalafil analogue found as an adulterant of a herbal product. Food Add Contam. 23:446-451.